Fulltext

DOTATOC: A powerful new tool for receptor-mediated radionuclide therapy

Otte, A. ; Jermann, E. ; Behe, M. ; Goetze, M. ; Bucher, H. ; Roser, H. ; Heppeler, A. ; Mueller-Brand, J. ; Maecke, H.

In: European Journal of Nuclear Medicine, 1997, vol. 24, no. 7, p. 792-795

Ajouter à la liste personnelle
    Titre
    • DOTATOC: A powerful new tool for receptor-mediated radionuclide therapy
    Auteur
    • Otte, A.. Institute of Nuclear Medicine, University Hospital, School of Medicine, Basel, Switzerland
    • Jermann, E.. Institute of Nuclear Medicine, University Hospital, School of Medicine, Basel, Switzerland
    • Behe, M.. Institute of Nuclear Medicine, University Hospital, School of Medicine, Basel, Switzerland
    • Goetze, M.. Institute of Nuclear Medicine, University Hospital, School of Medicine, Basel, Switzerland
    • Bucher, H.. Department of Internal Medicine, University Hospital, School of Medicine, Basel, Switzerland
    • Roser, H.. Department of Radiological Physics, University Hospital, School of Medicine, Basel, Switzerland
    • Heppeler, A.. Institute of Nuclear Medicine, University Hospital, School of Medicine, Basel, Switzerland
    • Mueller-Brand, J.. Institute of Nuclear Medicine, University Hospital, School of Medicine, Basel, Switzerland
    • Maecke, H.. Institute of Nuclear Medicine, University Hospital, School of Medicine, Basel, Switzerland
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • European Journal of Nuclear Medicine, 1997, vol. 24, no. 7, p. 792-795. Springer-Verlag
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:311548
    Summary
    This study presents the first successful use of a peptidic vector, DOTATOC, labelled with the β-emitting radioisotope yttrium-90, for the treatment of a patient with somatostatin receptor-positive abdominal metastases of a neuroendocrine carcinoma of unknown localization. Tumour response and symptomatic relief were achieved. In addition, the new substance DOTA-TOC was labelled with the diagnostic chemical analogue indium-111 and studied in three patients with histopathologically verified neuroendocrine abdominal tumours for its diagnostic sensitivity and compared with the commercially available OctreoScan. In all patients the kidney-to-tumour uptake ratio (in counts per pixel) was on average 1.9-fold lower with111In-DOTATOC than with OctreoScan. DOTATOC could be a potential new diagnostic and therapeutic agent in the management of neuroendocrine tumours